21 -5 (79) 2025 - Artikova S.G., Khaidarova N.B. - ISSUES OF IMPROVING THE QUALITY OF LIFE OF PATIENTS WITH METABOLIC FATTY LIVER DISEASE

ISSUES OF IMPROVING THE QUALITY OF LIFE OF PATIENTS WITH METABOLIC FATTY LIVER DISEASE

Artikova S.G. - Andijan State Medical Institute

Khaidarova N.B. - Andijan State Medical Institute

Primkulova G.N. - Andijan State Medical Institute

Mamajanov S.K. - Andijan State Medical Institute

Resume

Particular attention is paid to innovative strategies for liver tissue restoration and the possibility of using farnesoid receptor (FXR) agonists as a promising treatment option. FXR, as a nuclear receptor activated by ligands, plays a key role in the regulation of genes involved in metabolic processes, such as carbohydrate and lipid metabolism, bile acid metabolism and inflammation in the liver. Due to the ability to restore metabolic balance, FXR activator drugs can become a breakthrough solution for the treatment of NAFLD and associated diseases, providing a comprehensive effect on pathological processes in the liver.

Key words: metabolically associated fatty liver disease.

First page

103

Last page

105

For citation:Artikova S.G., Khaidarova N.B., Primkulova G.N., Mamajanov S.K. - ISSUES OF IMPROVING THE QUALITY OF LIFE OF PATIENTS WITH METABOLIC FATTY LIVER DISEASE//New Day in Medicine 5(79)2025 103-105 https://newdayworldmedicine.com/en/new_day_medicine/5-79-2025

List of References

1. Богомолов П.О., Павлова Т.В. Неалкогольный стеатогепатит: патофизиология, патоморфология, клиника и подходы к лечению // Фарматека. 2003;10:31-39.
2. Мишина Е.Е., Майоров А.Ю., Боголюбова А.В., Богомолов П.О., Мациевич М.В., Кокина К.Ю. Взгляд на новые терапевтические возможности у больных с неалкогольной жировой болезнью печени // Ожирение и метаболизм. 2019;16(3):37-45.
3. Полякова О.А., Козгунова Л.Д., Остроумова О.Д. Метаболически ассоциированная жировая болезнь печени: роль адеметионина // Фарматека. 2023;30(1-2):54-62.
4. Safadi R, Konikoff FM, Mahamid M, et al. The Fatty Acid-Bile Acid Conjugate Aramchol Reduces Liver Fat Content in Patients With Nonalcoholic Fatty Liver Disease. // Clin Gastroenterol Hepatol. 2014;12(12):2085-2091.e1
5. Yao J. FXR agonist GW4064 alleviates endotoxin-induced hepatic inflammation by repressing macrophage activation. // World J Gastroenterol. 2014;20(39):14430.
6. Yilmaz Y, Yonal O, Deyneli O, et al. Effects of sitagliptin in diabetic patients with nonalcoholic steatohepatitis. // Acta Gastroenterol Belg. 2012;75(2):240-244.

   file

   download